Connect with us

News

EQUITY ALERT: Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synchrony Financial – SYF

gbafNews28

Rosen Law Firm, a global investor rights law firm, announces the filing of a securities class action lawsuit on behalf of purchasers of the securities of Synchrony Financial (NYSE:SYF) from October 21, 2016 through November 1, 2018, inclusive (the Class Period). The lawsuit seeks to recover damages for Synchrony investors under the federal securities laws.

To join the Synchrony class action, go to https://www.rosenlegal.com/cases-1462.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTORS ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that Synchrony misrepresented that its consistent and disciplined underwriting practices had led to a higher quality loan portfolio than those of its competitors. In truth, Synchrony had relaxed its underwriting standards and increasingly offered private-label credit cards to riskier borrowers in order to sustain growth, which consequently damaged its relationship with retail partners.

On July 26, 2018, news outlets reported that Walmart had chosen a competitor to replace Synchrony. Then, on November 1, 2018, Walmart sued Synchrony, accusing it of improper underwriting in connection with a Walmart/Synchrony credit card program. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1462.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary
Halper, Esq.
275 Madison Avenue, 34th Floor
New
York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax:
(212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

News

Vinci Partners Announces Pricing of Initial Public Offering

gbafNews28

RIO DE JANEIRO, Jan. 27, 2021 /PRNewswire/ —  Vinci Partners Investments Ltd. (“Vinci Partners,” “the Company,” “we,” “us,” or “our”), the controlling company of a leading alternative investment platform in Brazil, today announced that it has priced its initial public offering of 13,873,474 Class A common shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a public offering price of $18.00 per share. The Class A common shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “VINP” on January 28, 2021 and the offering is expected to close on February 1, 2021, subject to customary closing conditions.

In connection with the offering, Vinci Partners has granted the underwriters a 30-day option to purchase up to an additional 2,081,021 Class A common shares at the initial public offering price, less underwriting discounts and commissions.

Vinci Partners intends to use the net proceeds from the offering to (1) to fund investments in its own products alongside its investors; (2) to pursue opportunities for strategic transactions; and (3) for other general corporate purposes.

J.P. Morgan, Goldman Sachs & Co. LLC and BTG Pactual are acting as global coordinators and joint bookrunners for the offering and Itaú BBA, BofA Securities, Credit Suisse and UBS Investment Bank are acting as joint bookrunners for the offering.

The offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: (i) J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at +1-866-803-9204, or by e-mail at [email protected]; (ii) Goldman Sachs & Co. LLC, Attention: Prospectus Department at 200 West Street, New York, NY, 10282, or by telephone at +1-212-902-1171, facsimile: +1-212-902-9316, or by email at [email protected]; (iii) Banco BTG Pactual S.A. — Cayman Branch, Attention: Prospectus Department, 601 Lexington Avenue, 57th Floor, New York, NY 10022, or by e-mail at [email protected]; (iv) Itau BBA USA Securities, Inc., 540 Madison Avenue 24th Floor, New York, New York 10022, Attention: Equity Sales Desk, telephone: 1-212-710-6756 or by emailing [email protected]; (v) BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or by calling 1-800-294-1322, or email [email protected]; (vi) Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at 1-800-221-1037 or by email at [email protected]; and (vii) UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, telephone: (888) 827-7275 or by emailing [email protected].

A registration statement on Form F-1 relating to these securities has been filed with, and declared effective by, the SEC. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The proposed offering has not been, and will not be, registered, in Brazil, with the Comissão de Valores Mobiliários – CVM, and the securities referred to herein shall not be offered in Brazil, according to Brazilian regulations.

About Vinci Partners

Vinci Partners is a leading alternative investment platform in Brazil, established in 2009. Our 205 full time employees as of September 30, 2020 draw from a wide-ranging network of personal and professional relationships with industry-leading executives, business owners, corporate managers, financial and operational advisors, consultants and attorneys to source, fund, and manage investments. Vinci Partners' business segments include private equity, public equities, real estate, credit, infrastructure, hedge funds, and investment products and solutions, each managed by dedicated investment teams with an independent investment committee and decision-making process. We also have a financial advisory business, focusing mostly on pre-initial public offering, or pre-IPO, and merger and acquisition, or M&A, advisory services for Brazilian middle-market companies.

We have established a premier independent investment franchise with market leadership across each of our high value-added strategies that we believe provide us with strong competitive advantages. We believe that our business model, focused on high-performance and executed by talented multi-disciplinary teams with a focus on value creation, has enabled us to build one of the most complete portfolios of alternative investment strategies and solutions, which combined with adoption of innovative technologies and increasing integration across our business segments, strongly positions us to capitalize on the future expansion and shifts in asset allocation in the Brazilian investments market.

USA Media Contact
Nick Lamplough / Kate Thompson / Katie Villany
Joele Frank, Wilkinson Brimmer Katcher
+1 (212) 355-4449

Brazil Media Contact
Danthi Comunicações
Carla Azevedo ([email protected])
+55 (21) 3114-0779

Investor Contact
[email protected]
NY: +1 (646) 559-8040
RJ: +55 (21) 2159-6240

Cision View original content:http://www.prnewswire.com/news-releases/vinci-partners-announces-pricing-of-initial-public-offering-301216707.html

SOURCE Vinci Partners

Continue Reading

News

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Management

gbafNews28

WINNIPEG, MB, Jan. 27, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI assessed by the rates of symptomatic and asymptomatic bleeding.

“Medicure is gratified and encouraged by the results of the trial led Dr. David Hasan, MD, Professor of Neurosurgery at University of Iowa Hospitals and Clinics, and the trial's principal investigator. His work is an important step in the exploration of the use of parenteral IV antiplatelet therapy in the management of aSAH in stroke patients.”, said Albert D. Friesen, PhD, CEO of Medicure and Chair of its Board of Directors. Dr. Hasan expects to release top-line data and present the results at an upcoming conference with a manuscript to follow.

Dr. Hasan states, “The results of iSPASM are very promising. The trial is the first of its kind as it showed in a well-designed, randomized controlled trial that using continuous IV infusion of AGGRASTAT® appears to be safe in patients with ruptured intracranial aneurysms (stroke). Results from this study pave the way for a Phase 2 trial which will be focused on efficacy. A positive outcome will be groundbreaking in the management of these patients. Interventionalists who treat patients with this condition using stents or flow diverters could use AGGRASTAT® as the choice of antiplatelet therapy to prevent clotting and further ischemic stroke. We are very grateful for the sponsorship and partnership with Medicure for making this trial happen to benefit our patients.”

iSPASM was funded by an unrestricted educational grant from Medicure. This study does not imply efficacy of AGGRASTAT® in patients with aSAH. Please note that the use of AGGRASTAT® in neurointerventions has not been approved by the FDA. As of this time, neither AGGRASTAT® nor any of the GP IIb/IIIa inhibitors are indicated for the use in stroke patients. AGGRASTAT® is approved for use in NSTE-ACS patients. Refer to Important Safety Information below and the U.S. Prescribing Information for complete product information.

About AGGRASTAT®
AGGRASTAT® is an IV antiplatelet medication indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT® is currently the most widely used GP IIb/IIIa inhibitor in the U.S.1 and has several administration benefits including room temperature storage, a 3-year shelf life and is available in pre-mixed formats. Please refer to the IMPORTANT SAFETY INFORMATION below.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (“Marley”), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley is committed to improving the health status of their patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit http://www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected]. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.

Important Safety Information for AGGRASTAT® (tirofiban hydrochloride)

Indications and Usage
AGGRASTAT® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Dosage and Administration
Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance ≤60 mL/min, give 25 mcg/kg within 5 minutes and then 0.075 mcg/kg/min.

Contraindications
Known hypersensitivity to any component of AGGRASTAT®, history of thrombocytopenia with prior exposure to AGGRASTAT®, active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month.

Warnings and Precautions 
AGGRASTAT® can cause serious bleeding. Most bleeding associated with AGGRASTAT® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue AGGRASTAT®.
Thrombocytopenia: Discontinue AGGRASTAT® and heparin.

Adverse Reactions
Bleeding is the most commonly reported adverse reaction.

For more information on AGGRASTAT®, please refer to Full Prescribing Information available at www.aggrastatHDB.com.

To be added to Medicure's e-mail list, please visit:        
http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words “believes”, “may”, “plans”, “will”, “estimates”, “continues”, “anticipates”, “intends”, “expects” and similar expressions, may constitute “forward-looking information” within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a PRV, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the “Risk Factors” section of its Form 20F for the year ended December 31, 2019.

AGGRASTAT® (tirofiban hydrochloride) injection is a registered trademark of Medicure International Inc.

References:

1.    Data on file

 

Cision View original content:http://www.prnewswire.com/news-releases/medicure-announces-early-completion-of-enrollment-for-ispasm-a-phase-12a-exploratory-clinical-trial-of-aggrastat-tirofiban-hydrochloride-injection-vs-placebo-for-induced-suppression-of-platelets-activity-in-aneurysmal-subara-301216718.html

SOURCE Medicure Inc.

Continue Reading

News

Fortis Lux Expands Services to Help Businesses Thrive Amid COVID Economy

gbafNews28

NEW YORK, Jan. 27, 2021 /PRNewswire/ — Fortis Lux Financial, a premier financial service organization with over $5 billion of assets serviced that helps businesses, families, and individuals achieve their financial goals, today announces the expansion of services to businesses and business owners who face an increasingly complex business, economic, and financial climate. These activities have led to continued growth of the firm's strategic partnership initiative, with the addition of Big Apple Accounting, Tax & Advisory.

“The COVID economy has pushed business owners and executives into making decisions amid uncertainty and turmoil,” explains John Salina, Managing Director, Fortis Lux. “We've developed a strategic partnership program to help ensure clients have access to the trusted professionals, resources, and technology they need to help them make decisions that will serve them well not only through the pandemic, but for generations to come.” 

Big Apple Accounting, Tax & Advisory (“BigAppleAccounting”) is a full-service CPA firm that offers monthly accounting, tax preparation, tax planning and outsourced CFO services to small business owners, high net worth individuals, medical practice owners, and entrepreneurs. In addition, Big Apple Accounting offers compilations, reviews and audits to small business owners.

This is the latest professional group to join in Fortis Lux's strategic partnership directive. Big Apple Accounting, Tax & Advisory, which has been providing both onsite and remote services since its inception 5 years ago, is uniquely positioned to help clients transition to and become acclimated with a remote business, accounting and financial operations model.  

This strategic partnership will allow BigAppleAccounting to provide clients access to additional financial services beyond accounting and tax services.  Working with Fortis Lux Financial, will allow BigAppleAccounting to offer current and future clients wealth management services, estate planning, investment planning, tax management, and retirement options. Clients will be offered access to a custom financial solution to support every stage of life. 

COVID has been the ultimate business disruptor, according to the latest MetLife & U.S. Chamber of Commerce Small Business Coronavirus Impact Poll with 55%* of businesses saying that it will be six months to a year before businesses return to what they would consider normal.  “As trying as these times have been, it has been exciting to work with clients through this crisis, and help clients take advantage of opportunities and build better, more sustainable and reliable businesses processes,” adds Busayo Ogunsanya CPA MST, Managing Partner, Big Apple Accounting, Tax and Advisory. “We have assisted clients with the payroll protection program, SBA EIDL loan, payroll protection program forgiveness, and SBA 7a Loan. The opportunity to simplify the financial client life and to produce a truly customized and comprehensive strategy focused on unique situations and priorities is something we are excited about!”

Fortis Lux is a comprehensive financial planning firm that offers wealth management, protection, risk management, trust and estate planning advice and solutions to address your present and future financial needs. For more information, visit www.FortisLux.com.

Big Apple Accounting, Tax & Advisory (“BigAppleAccounting”) is a full-service CPA firm that offers monthly accounting, tax preparation, tax planning and outsourced CFO services. For more information, visit www.BigAppleAccountingcpa.com or call:(646) 572-8621.

Securities and investment advisory services offered through qualified registered representatives of MML Investors Services, LLC. Member SIPC (www.SIPC.com). Supervisory Office 420 Lexington Avenue Fl 25, Suite 2510 New York, NY 10170. (212) 578-0300. Neither MML Investors Services, LLC nor any of its employees or agents are authorized to give legal or tax advice. Consult your own personal attorney legal or tax counsel for advice on specific legal and tax matters. Strategic partnership firms such as Big Apple Accounting, Tax and Advisory, are not affiliated with MML Investors Services, LLC. and are solely responsible for their own products and services provided. CRN202301-276648

Resources:
*https://www.uschamber.com/report/small-business-coronavirus-impact-poll-june

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fortis-lux-expands-services-to-help-businesses-thrive-amid-covid-economy-301216712.html

SOURCE Fortis Lux Financial

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News54 mins ago

BancorpSouth Bank Declares Quarterly Common & Preferred Dividends

TUPELO, Miss., Jan. 27, 2021 /PRNewswire/ — At its regular quarterly meeting today, the Board of Directors of BancorpSouth Bank (NYSE:...

gbafNews28 gbafNews28
News54 mins ago

SHAREHOLDER ALERT: WeissLaw LLP Investigates Kentucky Bancshares, Inc.

NEW YORK, Jan. 27, 2021 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by...

gbafNews28 gbafNews28
News54 mins ago

Jamul Indian Village Development Corporation Announces Refinance

JAMUL, Calif., Jan. 27, 2021 /PRNewswire/ — The Jamul Indian Village Development Corporation (JIVDC), owner and operator of Jamul Casino®, announced...

gbafNews28 gbafNews28
News54 mins ago

Old Point Releases Fourth Quarter and Full Year 2020 Results

HAMPTON, Va., Jan. 27, 2021 /PRNewswire/ — Old Point Financial Corporation (the Company or Old Point) (NASDAQ “OPOF”) reported net income of...

gbafNews28 gbafNews28
News54 mins ago

Fortis Lux Expands Services to Help Businesses Thrive Amid COVID Economy

NEW YORK, Jan. 27, 2021 /PRNewswire/ — Fortis Lux Financial, a premier financial service organization with over $5 billion of assets...

gbafNews28 gbafNews28
News54 mins ago

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Management

WINNIPEG, MB, Jan. 27, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company,...

gbafNews28 gbafNews28
News54 mins ago

Vinci Partners Announces Pricing of Initial Public Offering

RIO DE JANEIRO, Jan. 27, 2021 /PRNewswire/ —  Vinci Partners Investments Ltd. (“Vinci Partners,” “the Company,” “we,” “us,” or “our”),...

gbafNews28 gbafNews28
News54 mins ago

SHAREHOLDER ALERT: WeissLaw LLP Reminds ALSK, WDR, CBLI, and WTRE Shareholders About Its Ongoing Investigations

NEW YORK, Jan. 27, 2021 /PRNewswire/ — If you own shares in any of the companies listed above and would...

gbafNews28 gbafNews28
News54 mins ago

B. Riley Financial Commences Tender Offer for All Outstanding Shares of National Holdings Corporation

LOS ANGELES, Jan. 27, 2021 /PRNewswire/ — B. Riley Financial, Inc. (NASDAQ: RILY) (“B. Riley”), a diversified financial services and...

gbafNews28 gbafNews28
News54 mins ago

Investors Bancorp, Inc. Announces Fourth Quarter Financial Results and Cash Dividend

SHORT HILLS, N.J., Jan. 27, 2021 /PRNewswire/ — Investors Bancorp, Inc. (NASDAQ: ISBC) (“Company”), the holding company for Investors Bank (“Bank”),...